OREANDA-NEWS. "Grindeks" financial results of the first two months in 2013 show a 5% growth in turnover.

Referring to the information published by the BNS news agency, "Grindeks" confirms that, in accordance to the Group's annual budget of 2013 and the plan's performance during the first two months, compared to the same period of 2012, the financial results have been successful, reaching a 5% increase in turnover.

As reported previously, the company plans to reach the turnover of approximately 100 million lats and profit of approximately 12 million lats.

"Grindeks" specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups, but the company also has focused on other therapeutic directions. The registration of antimicrobial and other medications has been started in several CIS countries.

The company informs that it continually assesses export opportunities to the new markets. Currently it is negotiating with potential partners on exporting its products to Southeast Asian region.